By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.

Is your CCG getting it right first time?

By Editor
14th November 2020
Uncategorized

THIS IS AN ADVERTORIAL, SPONSORED BY TAKEDA UK LTD

GIRFT is a national NHS programme designed to improve medical care within the NHS by reducing unwarranted variations. By tackling variations in the way services are delivered across the NHS, and by sharing best practice between trusts, GIRFT identifies changes that will help improve care and patient outcomes, as well as delivering efficiencies such as the reduction of unnecessary complications along with the opportunity to realise cost savings.

GIRFT has recently published recommendations for diabetes.1 The clinical leads for the diabetes workstream – Professor Gerry Rayman and Professor Partha Kar – were appointed in 2017 and endorsed by the Association of British Clinical Diabetologists.

The recommendations highlight necessary improvements to services for people with Type 1 diabetes, inpatient diabetes care, diabetes footcare along with significant opportunities  for medicines optimization, specifically maximizing savings in DPP4-i treatments.

The report recommends the use of alogliptin in appropriate patients in order to improve the number of patients on appropriate lower cost therapy. This is the first time that specific direction has been given to CCGs to switch within the DPP-4 inhibitor class to a lower acquisition cost option in appropriate patients and is backed by NICE (NG28) guidance.

This cost-saving is too significant an opportunity to miss and could pay for initiatives such as additional nurses, fund new technologies and treatments to mention but a few. Since its launch in 2014, by using alogliptin in appropriate patients rather than another DPP-4i, the NHS has already saved £28 million.2

There is extreme variation in uptake of the use of alogliptin across England, from less than 1% to over 80% 2 (see figure 1):

Alogliptin is a DPP-4 inhibitor indicated in adults with Type 2 diabetes used in combination with other glucose lowering medicines, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.3Retrospective database analysis in primary care (865 patients) reported that a ‘within class’ switch to alogliptin did not compromise glycaemic control and was generally well tolerated.4

Experience from CCGs who have implemented a switch show that this is a relatively simple programme to implement, and significant cost-savings can be realised quickly.5

The increasing workload burden in primary care is a common barrier to implementing new programmes and initiatives. However, many CCGs who have been successful switching appropriate patients have done so when patients are called for their annual treatment review, which itself is an area of focus in terms of service provision as part of the GP contract framework.5

The GIRFT diabetes report recommends to switch appropriate patients with Type 2 diabetes on other DPP-4 inhibitors to alogliptin and to start appropriate new patients on alogliptin, presenting a great opportunity to not only save NHSE £20M over the next year, but also to improve overall patient care through more regular medicines review, and reinvesting savings into additional services.

References

  1. GIRFT diabetes report – https://www.gettingitrightfirsttime.co.uk/wp-content/uploads/2020/11/GIRFT-diabetes-report.pdf
  2. NHS Prescribing Data, as analysed by Takeda UK Ltd. Contains public sector information licensed under the Open Government Licence v3.0.
  3. Vipidia Summary of Product Characteristics: https://www.medicines.org.uk
  4. Strain WD, McEwan P, Howitt H, Meadowcroft S. Retrospective database analysis evaluating the clinical outcomes of changing treatment of people with Type 2 diabetes mellitus (T2DM) from other DPP-4 inhibitor therapy to alogliptin in a primary care setting. Diabetes Ther 2019;10 (4) :1499–1507.
  5. Cost saving analyses when switching appropriate patients from existing DPP-4 inhibitor to alogliptin within license – experiences across five CCG/Health Boards. Peter P, Unadkat M, Beusnard-Bee T. Presented at JoMO – UKCPA Joint Meeting. Medicines Optimisation in Diabetes, Manchester, May 2019.
  6. Network Contract Direct Enhanced Service: Draft Outline Service Specifications. https://www.engage.england.nhs.uk/survey/primary-care-networks-service-specifications/supporting_documents/Draft%20PCN%20Service%20Specifications%20December%202019.pdf Accessed November 2020.

Vipidia® (alogliptin) and Vipdomet® (alogliptin plus metformin) PRESCRIBING INFORMATION
Refer to summary of Product Characteristics (SmPC) before prescribing. Presentation:
VIPIDIA:  Alogliptin 6.25 mg, 12.5 mg and 25 mg film-coated tablets. VIPDOMET: Alogliptin plus metformin 12.5 mg/1000 mg film‑coated tablets. Indication: VIPIDIA: Adults (over 18 years) with Type 2 diabetes to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. VIPDOMET:Adults  (over 18 years ) with Type 2 diabetes as an adjunct to diet and exercise to improve glycaemic control in inadequately controlled patients on (1) their maximal tolerated dose of metformin alone, or already being treated with the combination of metformin and alogliptin (2) their maximal tolerated dose of metformin in combination with pioglitazone or (3) metformin in combination with insulin at a stable dose. Dosage & Administration: VIPIDIA:  One 25mg tablet mg once daily (o.d.) with or without food. VIPDOMET:One 12.5mg/1,000mg  tablet twice daily. The current metformin dose should be considered  and should be at a similar dose to that of Vipdomet. For patients switching from separate tablets of alogliptin and metformin, the current treatment regimen of alogliptin and metformin should be 25mg and 2,000mg per day respectively. Elderly: VIPIDIA/VIPDOMET: No dose adjustment is necessary. Renal impairment: VIPIDIA: Mild renal impairment, no dose adjustment. Moderate renal impairment 12.5 mg o.d. Severe renal impairment or end-stage renal disease requiring dialysis 6.25 mg o.d. Experience in patients on dialysis is limited.  Vipidia has not been studied in patients undergoing peritoneal dialysis. VIPDOMET: GFR 60-89mL/min, no dose adjustment. GFR 45-59 mL/min, maximum daily dose 12.5mg alogliptin and 2000mg metformin, GFR 30-44mL/min, maximum daily dose 12.5mg alogliptin and 1000mg metformin. If adequate strength of Vipdomet not available, use individual monocomponents instead. Contraindicated in severe renal failure (GFR<30 mL/min). Hepatic impairment: VIPIDIA: No dose adjustment is necessary in mild to moderate hepatic impairment. Not recommended for use in severe hepatic impairment. VIPDOMET: Should not be used in patients with hepatic impairment. Paediatric population: VIPIDIA/VIPDOMET: No data  available. Contraindications: VIPIDIA/VIPDOMET: Hypersensitivity to the active substance or to its excipients or history of a serious hypersensitivity reaction to any dipeptidyl-peptidase-4 (DPP-4) inhibitor.VIPDOMET: Acute metabolic acidosis, severe renal failure (eGFR<30 mL/min), acute conditions with the potential to alter renal function, acute or chronic disease which may cause tissue hypoxia (e.g. cardiac failure), hepatic impairment, acute alcohol intoxication, alcoholism. Warnings & Precautions: General: VIPIDIA/VIPDOMET: Do not use in Type 1 diabetes or for treatment of diabetic ketoacidosis. Use with other antihyperglycaemic medicinal products and hypoglycaemia: VIPIDIA: When used in combination with a sulphonylurea, insulin or combination therapy with thiazolidinedione plus metformin, a lower dose of these medications may be considered to reduce the risk of hypoglycaemia. VIPDOMET: Should not be used in combination with a sulphonylurea. When used in combination with insulin or pioglitazone, a lower dose of these medications may be considered to reduce the risk of hypoglycemia. Combinations not studied: VIPIDIA: Has not been studied in combination with sodium glucose cotransporter 2 (SGLT-2) inhibitors or glucagon like peptide 1 (GLP-1) analogues nor formally as triple therapy with metformin and sulphonylurea. Renal impairment: VIPIDIA/VIPDOMET: GFR should be assessed before treatment initiation and regularly thereafter. VIPDOMET: Metformin should be temporarily discontinued in the presence of conditions that alter renal function. Cardiac failure: VIPIDIA:  Caution for use in patients with congestive heart failure of New York Heart Association functional class III – IV due to limited experience. Hypersensitivity reactions: VIPIDIA/VIPDOMET: Anaphylactic reactions, angioedema and exfoliative skin conditions including Stevens-Johnson syndrome and erythema multiforme have been observed for DPP-4 inhibitors and have been spontaneously reported for alogliptin in the post-marketing setting.  Acute pancreatitis: VIPIDIA/VIPDOMET: Use of DPP-4 inhibitors have been associated with a risk of developing acute pancreatitis and so patients should be informed of the characteristic symptoms. If pancreatitis is suspected, Vipidia/Vipdomet should be discontinued; and if confirmed, not be restarted. Caution in patients with a history of pancreatitis. Hepatic effects: VIPIDIA/VIPDOMET:  Postmarketing reports of hepatic dysfunction, including failure, have been received. Patients should be observed for possible liver abnormalities and liver function should be tested promptly in patients with any symptoms. Discontinue Vipidia/Vipdomet treatment if an abnormality is found and an alternative aetiology is not established. Hepatic impairment: VIPIDIA: not recommended in severe hepatic impairment. VIPDOMET: see contraindications. Lactic acidosis: VIPDOMET: Greatest risk at acute worsening of renal function or cardiorespiratory illness or sepsis. Can occur with metformin accumulation. In case of dehydration, temporarily discontinue Vipdomet and contact a healthcare professional. Medicines that can impair renal function should be initiated with caution. Other risk factors include excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any condition associated with hypoxia. Inform patients/care-givers on risks and symptoms  and if suspected, discontinue Vipdomet and seek immediate medical attention. Surgery: VIPDOMET: Discontinue at the time of surgery and restart 48 or more hours following surgery or resumption of oral nutrition, provided renal function is stable. Administration of iodinated contrast agents: VIPDOMET: Due to potential risk of nephropathy and lactic acidosis, Vipdomet should be discontinued prior to, or at the time of, the test and not restarted until 48 hours afterwards, and only after renal function is stable. Change in clinical status of patients with previously controlled Type 2 diabetes: VIPDOMET: Patients who develop laboratory abnormalities or clinical illness should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. If acidosis of either form occurs, stop Vipdomet immediately. Interactions: VIPIDIA: Primarily excreted unchanged in the urine and metabolism by the cytochrome (P450 system is negligible. Studies show no clinically relevant pharmacokinetic interactions. VIPDOMET: Interactions with metformin: Not recommended with alcohol due to increased risk of lactic acidosis. Cationic medicinal products may interact with metformin – close monitoring recommended. Iodinated contrast agents – refer to warnings &  precautions section above.  Combinations requiring precautions for use: Closely monitor renal function when using with medicines that can affect renal function and increase risk of lactic acidosis. Medicinal products with intrinsic hyperglycaemic activity – glucocorticoids, beta‑2‑agonists, diuretics; or ACE inhibitors, which may lower blood glucose: dose of Vipdomet may need review during therapy with, and on stopping, the other medicinal product. Fertility, Pregnancy & Lactation: VIPIDIA/VIPDOMET: Avoid use during pregnancy. A risk to the breast-fed infant cannot be excluded. Consider the risk-benefit balance of use in breast-feeding mothers. The effect of Vipidia/Vipdomet on fertility in humans has not been studied. Undesirable Effects: VIPIDIA/ VIPDOMET: Common (≥1/100 to <1/10):  Upper respiratory tract infections; nasopharyngitis; hypoglycaemia; headache; abdominal pain; gastro-oesophageal reflux disease; pruritus; diarrhoea, rash. Other serious undesirable effects (frequency unknown): Acute pancreatitis; hepatic dysfunction including hepatic failure; angioedema; hypersensitivity; exfoliative skin conditions including Stevens-Johnson Syndrome, urticaria. In addition, VIPDOMET: Common (≥1/100 to <1/10):Gastroenteritis, diarrhoea, vomiting, gastritis. In addition, metformin only:  Very common (≥1/10): Abdominal pain, diarrhoea, loss of appetite, nausea, vomiting. Common (≥1/100 to <1/10) Metallic taste. Other serious undesirable effects (frequency very rare (<1/10,000)): Hepatitis, lactic acidosis. Refer to the SmPCs for details on full side effect profile and interactions. Basic NHS Price: VIPIDIA £26.60 for 28 tablets, VIPDOMET £26.60 for 56 tablets. Legal Classification: POM. Marketing Authorisations : VIPIDIA: EU/1/13/844/009 6.25 mg; EU/1/13/844/018 12.5 mg; EU/1/13/844/027 25 mg. VIPDOMET:  EU/1/13/843/017 Name and address of MA holder: Takeda UK Ltd, 1 Kingdom Street, London, W2 6BD. PI Approval Code:  UK/VIP/1912/0182 Date of revision: December 2019

VIPIDIA and VIPDOMET are registered trademarks of Takeda Pharmaceutical Company Limited.

C-APROM/UK/VIP/0228 Date of preparation: November 2020

Comments (0)

Register an account or login to comment